Skip to main content

RA Capital Management — Portfolio, Page 6

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
25
Industries
Biotechnology 21Health Care 13Medical 10Biopharma 9Life Science 8Therapeutics 7+19 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 121144 of 453
Ovid Therapeutics
March 2026

Ovid Therapeutic's purpose is to solve intractable medical problems.

Biopharma · New York$60.0M Post-IPO Equity
Curevo
March 2025

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

Biopharma · Bothell$110.0M Series B
Unicycive Therapeutics
March 2024

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with unmet medical needs.

Biotechnology · Los Altos$50.0M Post-IPO Equity
Equillium
March 2026

Equillium is a biotechnology company that develops products for autoimmune and inflammatory disorders with an unmet medical need.

Biopharma · La Jolla$35.0M Post-IPO Equity
Napigen
March 2024

NAPIGEN is a biotechnology company that addresses novel genome engineering of various organisms such as plants, microbes, and animals.

Agriculture · WilmingtonGrant
Dianthus Therapeutics
March 2026

Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.

Biopharma · Waltham$719.0M Post-IPO Equity
Angitia Biopharmaceuticals
February 2026

Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases.

Biopharma · Westlake Village$130.0M Series D
Apeiron labs
February 2026

Apeiron labs mission is to provide data from the upper of the ocean.

Analytics · Cambridge$9.5M Series A
Arcutis Biotherapeutics
February 2024

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.

Biopharma · Westlake Village$150.0M Post-IPO Equity
COMPASS Pathways
February 2026

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.

Biotechnology · Altrincham$200.0M Post-IPO Equity
Zura Bio
February 2026

Zura Bio is a clinical-stage, multi-asset biotechnology company.

Biopharma · Henderson$144.0M Post-IPO Equity
Bicara Therapeutics
February 2026

Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.

Biopharma · Cambridge$150.0M Post-IPO Equity
Tyra Biosciences
February 2024

Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.

Biotechnology · Carlsbad$200.0M Post-IPO Equity
Somatus
February 2022

Somatus is a healthcare company that partners with health plans, health systems, nephrology, and primary care groups.

Health Care · Mclean$325.0M Series E
Genetix Biotherapeutics Inc.
February 2025

Genetix Biotherapeutics develops and delivers approved gene therapies for severe rare genetic diseases like sickle cell.

Biotechnology · SomervillePrivate Equity
MMI
February 2024

MMI is focused on advancing robotic technology for soft tissue open surgery with the world's smallest wristed instruments.

Health Care · Pisa$110.0M Series C
Synthego
February 2022

Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.

Artificial Intelligence (AI) · Redwood City$200.0M Series E
Avilar Therapeutics
February 2023

Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.

Biotechnology · Waltham$15.0M Seed
Immunic Therapeutics
February 2026

Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.

Biotechnology · New York$400.0M Post-IPO Equity
Coherus Biosciences
February 2026

Coherus Biosciences develops, manufactures, and commercializes biologic therapeutics for oncology and inflammatory diseases.

Biotechnology · Redwood City$50.1M Post-IPO Equity
Evommune
February 2026

Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.

Biotechnology · Palo Alto$125.0M Post-IPO Equity
Abcuro
February 2025

Abcuro develops immunotherapies to treat autoimmunity and cancer.

Biotechnology · Newton$200.0M Series C
Xilio Therapeutics
February 2026

Xilio Therapeutics is a biotechnology company that develops tumor-activated immuno-oncology therapies.

Biopharma · Waltham$40.0M Post-IPO Equity
Galecto
February 2026

Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.

Biotechnology · Copenhagen$275.0M Post-IPO Equity

Where RA Capital Management invests

Biotechnology21
Health Care13
Medical10
Biopharma9
Life Science8
Therapeutics7

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Medical, Biopharma, Life Science. The firm invests across 25 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Dianthus Therapeutics received $719.0M in a Post-IPO Equity round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Ovid Therapeutics, Curevo, Unicycive Therapeutics, Equillium, Napigen. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →